messag follow result updat estim
beyond model call organ revenu growth year
better first cut adjust estim driven increas
contribut diagnost segment bottom line expect
ep fall yoy vs prior forecast declin result
demonstr resili diversifi portfolio believ safeti premium
fulli reflect stock share trade ep vs lc med-tech
better opportun elsewher group maintain neutral
model call adjust ep total revenu
organ compar prior forecast
respect vast major chang due see
improv outlook abbott diagnost busi cc estim
assum viral test revenu well posit impact
compani recent launch antibodi test forecast abbott
segment rel unchang number gener met expect
expect cardiovascular neuromodul sale declin cc impact elect
procedur postpon like peak next week could bleed
back half year elsewher expect continu strength diabet cc
solid growth establish pharma cc nutrit cc worth
note strong perform saw nutrit quarter cc like
outlier forecast assum pantri stock driven shelter place order
unwind cours next month
continu see abbott well posit weather current storm
much safeti premium alreadi reflect stock share
year date vs declin trade revis
ep estim repres signific premium large-cap med-tech group
believ abbott diversifi portfolio posit well sidestep worst
near-term disrupt face sector believ defens alreadi bake
premium valuat model continu call compani normal
top- bottom-lin growth moder next year level line
group averag believ stock risk multipl compress dust
settl result maintain neutral rate
sector medic suppli devic
page analyst certif import disclosur
abbott one largest healthcar compani world boast top line
lead franchis across medic devic diagnost nutrit establish
pharmaceut segment path get point long wind one
abbott reshuffl portfolio sever time past two decad recent
acquisit st jude medic aler deal help drive back-to-back
year top-lin gain low-double-digit earn growth benefit
acquisit mostli harvest see abbott growth moder stori
go forward model still call compani deliv normal ex-covid-
top bottom line gain respect compar
averag peer warrant premium valuat view
believ alreadi reflect stock
abbott share current trade ep estim
ebitda large-cap med-tech averag respect
believ abbott above-averag normal growth profil
peg top- bottom line respect vs group averag
warrant premium valuat believ alreadi reflect
stock model call top- bottom-lin growth moder
next year believ stock risk multipl compress better
opportun elsewher within large-cap med-tech group opinion
maintain neutral rate
upsid risk rate includ continu out-performance broader med-tech
group drive multipl expans sector adopt key new product
libr alin portico etc exceed street expect prudent
account model caus revenu growth exceed expect
drive earn leverag excess model
downsid risk rate includ pipelin setback and/or neg clinic result
impact abbott competit adopt key new product libr alin etc
fall short street expect macro weak emerg market countri
abbott outsiz exposur rel mani peer
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
point
compani report guggenheim secur llc estim
page analyst certif import disclosur
